Purevax RCCh

RSS

Lapsed

This medicine's authorisation has lapsed

vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections
MedicineVeterinaryLapsed

Irish is available via eTranslation, the European Commission's machine translation service.

Translate to Irish | Important information about machine translation

  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The marketing authorisation for Purevax RCCh has lapsed because it has not been marketed in the European Union in the three years following the granting of the authorisation.

български (BG) (1.23 MB - PDF)

Amharc

español (ES) (1.07 MB - PDF)

Amharc

čeština (CS) (1.17 MB - PDF)

Amharc

dansk (DA) (1.08 MB - PDF)

Amharc

Deutsch (DE) (1.08 MB - PDF)

Amharc

eesti (ET) (1.08 MB - PDF)

Amharc

ελληνικά (EL) (1.18 MB - PDF)

Amharc

français (FR) (1.08 MB - PDF)

Amharc

italiano (IT) (1.08 MB - PDF)

Amharc

latviešu (LV) (1.16 MB - PDF)

Amharc

lietuvių (LT) (1.17 MB - PDF)

Amharc

magyar (HU) (1.16 MB - PDF)

Amharc

Malti (MT) (1.17 MB - PDF)

Amharc

Nederlands (NL) (1.07 MB - PDF)

Amharc

polski (PL) (1.18 MB - PDF)

Amharc

português (PT) (1.08 MB - PDF)

Amharc

română (RO) (1.17 MB - PDF)

Amharc

slovenčina (SK) (1.17 MB - PDF)

Amharc

slovenščina (SL) (1.15 MB - PDF)

Amharc

suomi (FI) (1.07 MB - PDF)

Amharc

svenska (SV) (1.07 MB - PDF)

Amharc

Product information

български (BG) (374.27 KB - PDF)

Amharc

español (ES) (279.48 KB - PDF)

Amharc

čeština (CS) (356.65 KB - PDF)

Amharc

dansk (DA) (278.12 KB - PDF)

Amharc

Deutsch (DE) (348.87 KB - PDF)

Amharc

eesti (ET) (271.16 KB - PDF)

Amharc

ελληνικά (EL) (376.47 KB - PDF)

Amharc

français (FR) (271.82 KB - PDF)

Amharc

italiano (IT) (280.06 KB - PDF)

Amharc

latviešu (LV) (367.85 KB - PDF)

Amharc

lietuvių (LT) (172.31 KB - PDF)

Amharc

magyar (HU) (359.84 KB - PDF)

Amharc

Malti (MT) (373.08 KB - PDF)

Amharc

Nederlands (NL) (277.75 KB - PDF)

Amharc

polski (PL) (382.15 KB - PDF)

Amharc

português (PT) (113.33 KB - PDF)

Amharc

română (RO) (171.68 KB - PDF)

Amharc

slovenčina (SK) (367.23 KB - PDF)

Amharc

slovenščina (SL) (354.17 KB - PDF)

Amharc

suomi (FI) (274.18 KB - PDF)

Amharc

svenska (SV) (271.32 KB - PDF)

Amharc
Latest procedure affecting product information:R/0007
12/02/2014

български (BG) (656.37 KB - PDF)

Amharc

español (ES) (1.03 MB - PDF)

Amharc

čeština (CS) (644.91 KB - PDF)

Amharc

dansk (DA) (593.89 KB - PDF)

Amharc

Deutsch (DE) (600.45 KB - PDF)

Amharc

eesti (ET) (587.75 KB - PDF)

Amharc

ελληνικά (EL) (808.99 KB - PDF)

Amharc

français (FR) (588.65 KB - PDF)

Amharc

italiano (IT) (596.67 KB - PDF)

Amharc

latviešu (LV) (641.54 KB - PDF)

Amharc

lietuvių (LT) (637.85 KB - PDF)

Amharc

magyar (HU) (619.22 KB - PDF)

Amharc

Malti (MT) (648.17 KB - PDF)

Amharc

Nederlands (NL) (599.84 KB - PDF)

Amharc

polski (PL) (1.07 MB - PDF)

Amharc

português (PT) (600.34 KB - PDF)

Amharc

română (RO) (645.37 KB - PDF)

Amharc

slovenčina (SK) (644.69 KB - PDF)

Amharc

slovenščina (SL) (625.67 KB - PDF)

Amharc

suomi (FI) (587.85 KB - PDF)

Amharc

svenska (SV) (588.17 KB - PDF)

Amharc

Íslenska (IS) (594.57 KB - PDF)

Amharc

norsk (NO) (598.77 KB - PDF)

Amharc

Product details

Name of medicine
Purevax RCCh
Active substance
  • attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)
  • inactivated feline calicivirosis antigens (FCV 431 and G1 strains)
  • attenuated Chlamydophila felis (905 strain)
International non-proprietary name (INN) or common name
vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections
Species
Cats
Anatomical therapeutic chemical veterinary (ATCvet) code
QI06AH

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged 8 weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs and excretion;
  • against Chlamydophila felis infection to reduce clinical signs.

Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and Chlamydophila felis components.

The duration of immunity is 1 year after the last (re-)vaccination.

Authorisation details

EMA product number
EMEA/V/C/000092
Marketing authorisation holder
Merial

29 Avenue Tony Garnier
69007 Lyon
France

Marketing authorisation issued
22/02/2005
Lapse of marketing authorisation
22/02/2008
Revision
8

Assessment history

This page was last updated on

Share this page